Traian Dumitrascu

Dr. Traian Dumitrascu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2019 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
MDMihnea P. Dragomir
Mihnea P. Dragomir
ASAlexandru A. Sabo
Alexandru A. Sabo
GPGeorge Petrescu
George Petrescu
YLYongfeng Li
Yongfeng Li
TDTraian Dumitrascu
Traian Dumitrascu

13 February 2023 in Medicina
Verified
Journal Article
Open access
PDF file
IDIoana Mihaela Dinu
Ioana Mihaela Dinu
MMMariana Mihaila
Mariana Mihaila
MDMihai Mircea Diculescu
Mihai Mircea Diculescu
VCVlad Mihai Croitoru
Vlad Mihai Croitoru
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
Adina Emilia Emilia CroitoruAdina Emilia Emilia Croitoru
Adina Emilia Emilia Croitoru
Background and Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related mortality and morbidity worldwide. Bevacizumab was approved for the treatment of metastatic colorectal cancer (mCRC) based on favorable benefit-risk assessments from randomized controlled trials, but evidence on its use in the real-world setting is limited. The aim of the current study is to evaluate the outcomes and safety profile of bevacizumab in mCRC in a real-world setting in Romania. Patients and Methods: This was an observational, retrospective, multicentric, cohort study conducted in Romania that included patients with mCRC treated with bevacizumab as part of routine clinical practice. Study endpoints were progression-free survival, overall survival, adverse events, and patterns of bevacizumab use. Results: A total of 554 patients were included in the study between January 2008 and December 2018. A total of 392 patients (71%) received bevacizumab in the first line and 162 patients (29%) in the second line. Bevacizumab was mostly combined with a capecitabine/oxaliplatin chemotherapy regimen (31.6%). The median PFS for patients treated with bevacizumab was 8.4 months (interquartile range [IQR], 4.7–15.1 months) in the first line and 6.6 months (IQR, 3.8–12.3 months) in the second line. The median OS was 17.7 months (IQR, 9.3–30.6 months) in the first line and 13.5 months (IQR, 6.7–25.2 months) in the second line. Primary tumor resection was associated with a longer PFS and OS. The safety profile of bevacizumab combined with chemotherapy was similar to other observational studies in mCRC. Conclusions: The safety profile of bevacizumab was generally as expected. Although the PFS was generally similar to that reported in other studies, the OS was shorter, probably due to the less frequent use of bevacizumab after disease progression and the baseline patient characteristics. Patients with mCRC treated with bevacizumab who underwent resection of the primary tumor had a higher OS compared to patients with an unresected primary tumor.

1 January 2021 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
AMAlexandru Martiniuc
Alexandru Martiniuc
TDTraian Dumitrascu
Traian Dumitrascu
MIMihnea Ionescu
Mihnea Ionescu
STStefan Tudor
Stefan Tudor
MLMonica Lacatus
Monica Lacatus
CVCatalin Vasilescu
Catalin Vasilescu
Martiniuc A, et al. J Gastric Cancer. 2021 Mar;21:e3. https://doi.org/10.5230/jgc.2021.21.e3

1 January 2016 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
RDRadu Dumitru
Radu Dumitru
ACAna Carbunaru
Ana Carbunaru
Mugur Cristian GrasuMugur Cristian Grasu
Mugur Cristian Grasu
MTMihai Toma
Mihai Toma
MIMihnea Ionescu
Mihnea Ionescu
TDTraian Dumitrascu
Traian Dumitrascu
Delayed post-pancreatectomy hemorrhage (PPH) is a relatively uncommon, but feared, complication after pancreaticoduodenectomy (PD). A splenic artery pseudoaneurysm is a rare cause of delayed PPH after a PD. This paper describes the case of a patient with PD used to treat a distal bile duct cholangiocarcinoma complicated with a clinically significant pancreatic fistula and secondary intraabdominal abscess. Computed tomography-guided drainage of the abscess was performed with an apparently favourable outcome; the patient was discharged on postoperative day (POD) 35 and the abdominal drains were removed on POD 50. On POD 80, the patient was readmitted for a severe digestive hemorrhage. Computed tomography revealed a pseudoaneurysm of the splenic artery with a subsequent hematoma formation. Immediately, an angiography was performed and coils were successfully mounted. This case illustrates the rare possibility of the development of a splenic artery pseudoaneurysm with severe delayed PPH after PD complicated with a clinically significant pancreatic fistula, even after the patient was discharged from the hospital. An interventional radiology approach represents the first treatment option in hemodynamically stable patients with high success rates.

1 January 2017 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
PDF file
TDTraian Dumitrascu
Traian Dumitrascu
ASAndra Scarlat
Andra Scarlat
MIMihnea Ionescu
Mihnea Ionescu
IPIrinel Popescu
Irinel Popescu
Dumitrascu T, et al. Ann Hepatobiliary Pancreat Surg. 2017 May;21(2):76-79. https://doi.org/10.14701/ahbps.2017.21.2.76

18 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BTBeatrice Mihaela Tivadar
Beatrice Mihaela Tivadar
TDTraian Dumitrascu
Traian Dumitrascu
CVCatalin Vasilescu
Catalin Vasilescu
Background: Many papers exploring the role of resectioning metastases in colorectal cancer (CRC) have focused mainly on liver and lung sites, showing improved survival compared with non-resectional therapies. However, data about exceptional metastatic sites such as splenic metastases (SMs) are scarce. This paper aims to assess the role and effectiveness of splenectomy in the case of isolated metachronous SM of CRC origin. Methods: The patients’ data were extracted after a comprehensive literature search through public databases for articles reporting patients with splenectomies for isolated metachronous SM of CRC origin. Potential predictors of survival were explored, along with demographic, diagnostic, pathology, and treatment data for each patient. Results: A total of 83 patients with splenectomies for isolated metachronous SM of CRC origin were identified. The primary CRC was at an advanced stage (Duke’s C—70.3%) and on the left colon (45.5%) for most patients, while the median interval between CRC resection and SM was 24 months. The median overall survival after splenectomy was 84 months, and patients younger than 62 years presented statistically significantly worse overall survival rates than those ≥62 years old (p = 0.011). There was no significant impact on the long-term outcomes for factors including primary tumor location or adjuvant chemotherapy (p values ≥ 0.070, ns). Laparoscopic splenectomy was increasingly used in the last 20 years from 2002 (33.3% vs. 0%, p < 0.001). Conclusions: Splenectomy is the optimal treatment for patients with isolated metachronous SM of CRC, with the laparoscopic approach being increasingly used and having the potential to become a standard of care. Encouraging long-term survival rates were reported in the context of a multidisciplinary approach. Younger ages are associated with worse survival. Perioperative chemotherapy in the context of a patient diagnosed with SM of CRC origin appears to be a reasonable option, although the present study failed to show any significant impact on long-term survival.